ePRO Monitoring Cut Fatigue in Metastatic Breast Cancer
Key Takeaways
- In women with metastatic breast cancer receiving systemic therapy, weekly alert-based ePRO monitoring was associated with lower 6-month fatigue than usual care, and the difference exceeded the prespecified threshold for clinical importance.
- Physical functioning at 6 months was higher with weekly alert-based monitoring, and the between-group difference exceeded its prespecified threshold for clinical importance.
- The 6-month quality-of-life difference was statistically significant but remained below the prespecified threshold for clinical importance.
- Baseline fatigue scores favored the intervention group.
Women with metastatic breast cancer receiving systemic therapy were enrolled in a multicenter randomized clinical trial at 52 breast cancer centers in Germany with 12 months of follow-up. 2,008 women were screened, 924 were randomized, and 909 were included in the primary analysis. The intervention used weekly smartphone patient-reported outcome (PRO) questionnaires based on validated European Organisation for Research and Treatment of Cancer (EORTC) computerized adaptive testing short forms, with automated alerts for predefined deterioration and clinician or nurse telephone contact within 48 hours; usual care used quarterly questionnaires without alerts. Fatigue at 6 months was the primary endpoint, and physical functioning and quality of life over 12 months were secondary outcomes reported as standardized T scores.
At 6 months, adjusted fatigue was 5.4 T-score points lower with alert-based monitoring, exceeding the prespecified 3.3-point threshold for clinical importance. Physical functioning was 4.0 points higher, exceeding its 3.2-point threshold, whereas the 0.8-point quality-of-life difference was statistically significant but below its 2.9-point threshold.
Interpretation of the fatigue finding is tempered by the starting point of the two groups: baseline fatigue T scores were 57.6 in the intervention group and 60.2 in the control group (P < .001), and baseline PROs were collected after randomization but before group-specific follow-up began. Because the trial was conducted across German breast cancer centers, the findings most directly reflect that care setting rather than a specifically North American pathway.
The investigators reported that digital PRO monitoring was associated with clinically meaningful fatigue reduction and improved physical functioning in this randomized trial, while the quality-of-life difference did not reach the prespecified threshold for clinical importance. They said the findings support further evaluation of alert-based PRO monitoring in routine oncology care.
Clinician Questions
Which patients were included in the trial of alert-based PRO monitoring for metastatic breast cancer?
The trial enrolled adult women with metastatic breast cancer who were receiving systemic therapy at any point in the metastatic disease course, had a life expectancy longer than 3 months, could read German, and had smartphone access. Because participation was limited to patients treated across German breast cancer centers, those criteria define the population to which the reported findings most directly apply.
How did weekly alert-based PRO monitoring differ from usual care in metastatic breast cancer?
The intervention used weekly smartphone PRO questionnaires with automated alerts for predefined deterioration and rapid clinician or nurse telephone follow-up, whereas usual care used quarterly PRO questionnaires without alerts. The comparison therefore centered on more frequent remote symptom surveillance paired with alert-triggered contact versus routine follow-up without that response system.
What trial detail most affects interpretation of the fatigue benefit with digital PRO monitoring in metastatic breast cancer?
The abstract highlights that baseline fatigue was already lower in the intervention group. That feature is central context for interpreting the between-group fatigue difference.